US4309418A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-tumor agent from human serum and process
Assignee: Memorial Sloan Kettering Cancer Center
•
Filing: 1980-03-25
•
Granted: 1982-01-05
•
Expires: 2000-03-25
Abstract
Abstract The invention relates to an anti-tumor agent prepared from human serum by the process steps of multiple salting out, centrifuging, desalting and gel filtration.
Inventors
- 👤 Saul Green
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 17:24
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
156 words
Process for preparing an anti-tumor agent from buffered human serum which comprises: (i) removing a first portion of proteins from the serum by addition of ammonium sulfate salt in an amount up to about 35% of the amount necessary to form a saturated solution while maintaining the pH at 7; thereafter (ii) centrifuging the serum at a force of 105,000 g to separate the first portion of proteins, and discarding the first portion of proteins; (iii) recovering a second portion of proteins from the serum by addition of ammonium sulfate salt in an amount to total an amount greater than about 35% up to about 70% of the amount necessary to form a saturated solution while maintaining the pH at 7, and retaining the second portion of proteins; (iv) desalting the second portion of proteins; (v) gel filtering the desalted proteins; and (vi) collecting a gel filtered active fraction having a molecular weight greater than 150,000.
Claim 2
Dependent Claim
156 words
Process for preparing an anti-tumor agent from buffered human serum which comprises: (i) removing a first portion of proteins from the serum by addition of ammonium sulfate salt in an amount up to about 35% of the amount necessary to form a saturated solution while maintaining the pH at 7; thereafter (ii) centrifuging the serum at a force of 105,000 g to separate the first portion of proteins, and discarding the first portion of proteins; (iii) recovering a second portion of proteins from the serum by addition of ammonium sulfate salt in an amount to total an amount greater than about 35% up to about 70% of the amount necessary to form a saturated solution while maintaining the pH at 7, and retaining the second portion of proteins; (iv) desalting the second portion of proteins; (v) gel filtering the desalted proteins; and (vi) collecting a gel filtered active fraction having a molecular weight greater than 150,000.
Claim 3
Dependent Claim
16 words
Process of claim 1 wherein fats are removed before salting out the first portion of proteins.
Claim 4
Dependent Claim
9 words
Process of claim 1 carried out under sterile conditions.
Claim 5
Dependent Claim
21 words
Process of claim 1 wherein an isotonic buffer is added to the serum before salting out the first portion of proteins.
Claim 6
Dependent Claim
25 words
Process of claim 4 wherein the isotonic buffer is an aqueous solution of about 0.05 molar potassium phosphate containing about 0.9 percent of sodium chloride.
Claim 7
Dependent Claim
28 words
Process of claim 1 wherein dialysis is carried out with a membrane having a pore size which excludes molecules having a molecular weight of more than about 10,000.
Claim 8
Dependent Claim
13 words
Process of claim 1 wherein the filtering gel is a polyacrylamide dextran gel.
Claim 9
Dependent Claim
16 words
Process of claim 1 further comprising separating and extracting the active fraction on a semisolid gel.
Claim 10
Dependent Claim
55 words
The process of claim 1 wherein said first portion of proteins is removed by an addition of sufficient salt to form an approximately 35% saturated solution; and said second portion of proteins is recovered by an addition of sufficient salt to form an approximately 70% saturated solution; thereby to optimize the recovery of said agent.
Claim 11
Dependent Claim
38 words
Anti-tumor agent derived from human serum comprising a protein fraction having a molecular weight of more than 150,000 which is stable at 90° C. for at least one hour, non-dialyzable and inhibits the growth of HeLa tumor cells.
Claim 12
Dependent Claim
38 words
Anti-tumor agent derived from human serum comprising a protein fraction having a molecular weight of more than 150,000 which is stable at 90° C. for at least one hour, non-dialyzable and inhibits the growth of HeLa tumor cells.
Claim 13
Dependent Claim
23 words
Anti-tumor agent of claim 10 in an aqueous solution having a concentration of said agent of from about 0.1 to about 2.5 percent.
Claim 14
Dependent Claim
10 words
Anti-tumor agent of claim 11 in an isotonic aqueous solution.
Claim 15
Dependent Claim
6 words
Anti-tumor agent of claim 10 lyophilized.
Claim 16
Dependent Claim
21 words
Process inhibiting the growth of tumor cells comprising contacting the tumor cell lines in vitro with the product of claim 10.
References Cited (Backward Citations)
US2876168A
Cited
GB845611A
Cited
US3105798A
Cited
US3151027A
Cited
US3105013A
Cited
US3257282A
Cited
US3282792A
Cited
US3337412A
Cited
US3330732A
Cited
US3445567A
Cited
US3378445A
Cited
US3756386A
Cited
US4009257A
Cited
US3804946A
Cited
US4016255A
Cited
US4076701A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-01-04 | 1985-07-06 | 1986-01-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-01-04 | 1989-07-06 | 1990-01-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-01-04 | 1993-07-06 | 1994-01-05 | $7700.00 | Window Closed / Lapsed |